aromatase inhibitor Clinical Research Trials

Please select a valid location from the dropdown

Found 81 clinical trials

featured

A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) (ECOG E1Z11

musculoskeletal diseases

102 views
23 Nov, 2020
1 location

featured

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

advanced breast cancer

breast cancer

endocrine therapy

hormone therapy

88 views
23 Nov, 2020
1 location

featured

CTSU/ECOG E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

34 views
08 Nov, 2020
1 location

featured

SWOG S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer

46 views
08 Nov, 2020
1 location

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence of an aromatase inhibitor in first line followed by fulvestrant plus CDK4/6 in second line.

liver metastases

endocrine therapy

cancer

breast cancer

gilbert's syndrome

71 views
23 Jan, 2021
72 locations

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of

0 views
16 Feb, 2021
48 locations

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

50 views
24 Feb, 2021
203 locations

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …

paclitaxel

fluorouracil

her2/neu-positive breast cancer

tamoxifen

epirubicin

33 views
07 Nov, 2020
1 location

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely

serum luteinizing hormone

luteinizing hormone

anastrozole

aromatase inhibitor

letrozole

38 views
08 Nov, 2020
1 location

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

(HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose disease has progressed on or after aromatase inhibitor (AI) treatment regardless of prior CDK4/6 inhibitor use.

human epidermal growth factor

cish

her2-negative breast cancer

measurable disease

PIK3CA

0 views
27 Jan, 2021
4 locations

Filter By

Found 81 clinical trials